The Readout Loud
221: Big egos in Big Science, the return of Merger Monday, & the fallout over drug pricing
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Are biotech's fortunes finally changing? Is Big Science impeding actual science? And what will Medicare negotiation mean for drug prices? STAT's Jason Mast joins us to discuss Jim Wilson, a pioneering scientist synonymous with the rise of gene therapy who staffers say presided over a toxic, abusive workplace. We also explain the latest news in the life sciences, including a multibillion-dollar deal, a novel approach to treating schizophrenia, and what the Senate drug pricing legislation means for the pharmaceutical industry.